Cypress Prosorba Rheumatoid Arthritis PMA Submission Slated For Mid-year
This article was originally published in The Gray Sheet
Cypress Bioscience is planning a mid-1998 premarket approval application submission for the Prosorba immunoadsorption column in treating severe rheumatoid arthritis, the San Diego-based company says.
You may also be interested in...
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”
The Onyx One Clear study, evaluating the Resolute Onyx drug-eluting stent in high bleeding risk patients, met its primary endpoint at the one-year follow up.